

Cytokeratin Cocktail Broad Spectrum Primary Antibody

Clone: AE1+AE3+C51 (Mouse Monoclonal)

Localization – Cytoplasm, membrane

Host Species – Mouse

Ig Class – IgG1, kappa

ORDERING INFORMATION	
CATALOG#	DESCRIPTION
DH548-01C	0.1 ML Concentrated Antibody Vial
DH548-05C	0.5 ML Concentrated Antibody Vial
DH548-1C	1 ML Concentrated Antibody Vial
DH548-3R	3 ML Ready-to-Use Antibody Vial
DH548-6R	6 ML Ready-to-Use Antibody Vial
DH548-12R	12 ML Ready-to-Use Antibody Vial

Intended Use

This antibody is designed for the specific localization of Cytokeratin Cocktail Broad Spectrum in formalin-fixed, paraffin-embedded (FFPE) tissue sections.

Storage & Handling

Store RTU Vial at 2-8°C. Fresh dilutions for concentrated antibodies, if required, should be prepared prior to use and are stable for up to one day at room temperature (20-26°C).

Working Principle

IHC is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or any Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Product Description

Cytokeratins are intermediate filament proteins essential for the structural integrity of epithelial cells. They are expressed in a tissue-specific and differentiation-dependent manner, making them highly valuable markers for epithelial cell identification and tumor classification. The Cytokeratin Cocktail Broad Spectrum combines three monoclonal antibodies: Clone AE1 – reacts with acidic type I cytokeratins (CK10, 14, 15, 16, 19). Clone AE3 – reacts with basic type II cytokeratins (CK1–8). Clone C51 – specifically detects CK8 and CK18, enhancing sensitivity for simple epithelia and adenocarcinomas. This combination provides broad coverage across low- and high-molecular-weight cytokeratins, enabling reliable detection of most epithelial tissues and their neoplastic counterparts.

Material Supplied

Cytokeratin Cocktail Broad Spectrum antibody is affinity purified and diluted in PBS, pH 7.4, containing 1% BSA and 0.09% sodium azide.

Material required But Not Supplied

- Xylene
- Isopropyl alcohol
- Positive charged slides
- Wash Buffer
- DI Water
- Antigen retrieval buffers
- Blocking Reagents
- Detection System
- Control Tissues
- Hematoxylin
- Mounting media
- Cover glass

Working Reagent Procedure

- Ready-to-Use antibodies have been optimized for use with the recommended protocols and should not require further dilution.
- Concentrated antibodies must be diluted in accordance with the recommended protocol.

Recommended Protocol

Refer the following table for the details on specific recommended protocol for this antibody.

Control Tissue	Tonsil, skin, or colon	Antibody Incubation Time	30-60 Minutes at RT
Dilution factor	1:20-50 (Antibody Diluent: DH144)	Retrieval Pre-treatment	Tris-EDTA based HIER (AR9 Buffer: DH020)

Precautions

This product should be used by qualified and trained professional users only.

Avoid microbial contamination of reagents to minimize non-specific staining. Never pipette reagents by mouth. Avoid contact of reagents and specimens with skin. If reagents or specimens come into contact with sensitive area, wash with sufficient amounts of water. Dispose of the unused reagents. This kit contain sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at these concentrations, but proper handling protocols should be observed. For more information on product hazards, precautions and waste disposal, *Material Safety Data Sheets* are available upon request.

Limitations

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure. Evaluation must be performed by a qualified pathologist.

Troubleshooting

For Technical Support contact us at +91 - 7506501122 or info@dygnova.com or your local distributor to report unusual staining.

Doc No: DH/DS/PRL535Rev.00

	Manufacturer Details		Use by Date		Lot/Batch Number
	Manufacturing Date		Consult Instructions for Use		Catalogue Number
	Temperature Limits		Sufficient for 'n' assays / tests		In-vitro Diagnostic Medical Device